Cargando…

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial

PARP inhibitors are approved for treating advanced prostate cancers (APC) with various defective DNA repair genes; however, further studies to clinically qualify predictive biomarkers are warranted. Herein we analyzed TOPARP-B phase II clinical trial samples, evaluating whole-exome and low-pass whol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carreira, Suzanne, Porta, Nuria, Arce-Gallego, Sara, Seed, George, Llop-Guevara, Alba, Bianchini, Diletta, Rescigno, Pasquale, Paschalis, Alec, Bertan, Claudia, Baker, Chloe, Goodall, Jane, Miranda, Susana, Riisnaes, Ruth, Figueiredo, Ines, Ferreira, Ana, Pereira, Rita, Crespo, Mateus, Gurel, Bora, Nava Rodrigues, Daniel, Pettitt, Stephen J., Yuan, Wei, Serra, Violeta, Rekowski, Jan, Lord, Christopher J., Hall, Emma, Mateo, Joaquin, de Bono, Johann S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414325/ https://www.ncbi.nlm.nih.gov/pubmed/34045297 http://dx.doi.org/10.1158/2159-8290.CD-21-0007

Ejemplares similares

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
por: Mateo, Joaquin, et al.
Publicado: (2020)

Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer
por: Paschalis, Alec, et al.
Publicado: (2019)

Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency
por: Zafeiriou, Zafeiris, et al.
Publicado: (2019)

Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA
por: Sumanasuriya, Semini, et al.
Publicado: (2021)

HER3 Is an Actionable Target in Advanced Prostate Cancer
por: Gil, Veronica, et al.
Publicado: (2021)

Germline ATM Mutations Detected by Somatic DNA Sequencing in Lethal Prostate Cancer
por: Grochot, Rafael, et al.
Publicado: (2023)

Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer
por: Sheehan, Beshara, et al.
Publicado: (2022)

Genomics of lethal prostate cancer at diagnosis and castration resistance
por: Mateo, Joaquin, et al.
Publicado: (2020)

Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers
por: Rescigno, Pasquale, et al.
Publicado: (2018)

A decade of clinical development of PARP inhibitors in perspective
por: Mateo, J, et al.
Publicado: (2019)

Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail
por: Ong, M, et al.
Publicado: (2014)

Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab
por: Minchom, Anna, et al.
Publicado: (2020)

Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses
por: Lorente, David, et al.
Publicado: (2016)

Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance
por: Guo, Christina, et al.
Publicado: (2023)

Opinion: PARP inhibitors in cancer—what do we still need to know?
por: Wicks, Andrew J., et al.
Publicado: (2022)

HER3 expression and MEK activation in non-small-cell lung carcinoma
por: Manickavasagar, Thubeena, et al.
Publicado: (2021)

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
por: Sharp, Adam, et al.
Publicado: (2018)

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
por: Ferraldeschi, Roberta, et al.
Publicado: (2015)

High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy
por: Perez-Lopez, Raquel, et al.
Publicado: (2017)

A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer
por: Kolinsky, M.P., et al.
Publicado: (2020)

Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)
por: Mehra, Niven, et al.
Publicado: (2018)

A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant
por: Pettitt, Stephen J., et al.
Publicado: (2023)

Acquiring evidence for precision prostate cancer care
por: Mateo, J., et al.
Publicado: (2017)

Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer
por: Welti, Jonathan, et al.
Publicado: (2016)

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
por: Nava Rodrigues, Daniel, et al.
Publicado: (2018)

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
por: Pettitt, Stephen J., et al.
Publicado: (2018)

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
por: Yap, Timothy A., et al.
Publicado: (2020)

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors
por: Papadatos-Pastos, Dionysis, et al.
Publicado: (2022)

BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance
por: Wang, Yifan, et al.
Publicado: (2019)

Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer
por: Lorente, David, et al.
Publicado: (2016)

A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity
por: Pettitt, Stephen J., et al.
Publicado: (2013)

CD38 in Advanced Prostate Cancers
por: Guo, Christina, et al.
Publicado: (2021)

Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition
por: Aziz, Diar, et al.
Publicado: (2021)

SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
por: Llorca-Cardenosa, Marta J., et al.
Publicado: (2022)

The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin
por: Krastev, Dragomir B., et al.
Publicado: (2022)

Beyond DNA repair: the novel immunological potential of PARP inhibitors
por: Chabanon, Roman M., et al.
Publicado: (2019)

Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies
por: Yélamos, José, et al.
Publicado: (2020)

PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling
por: van Beek, Lotte, et al.
Publicado: (2021)

The promise of circulating tumor cell analysis in cancer management
por: Mateo, Joaquin, et al.
Publicado: (2014)

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
por: Serra, Violeta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vit4dq3614t6ed7dev2950pa66